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O1. Current literature highlights
1.1. Small molecule non-chiral renin inhibitors
One of the major risk factors for cardiovascular diseases
such as congestive heart failure, stroke and myocardial
infarction is hypertension. Hypertension is the leading
cause of death in the western world and it is estimated that
there are approximately 1 billion people worldwide that
suﬀer from high blood pressure. Despite currently available
therapies, the majority of patients diagnosed with hyper-
tension do not reach their target blood pressure levels.
Opportunities remain for improved treatment options
and the renin–angiotensin system (RAS) is well established
as a key point of intervention with a system involved in
blood pressure and ﬂuid electrolyte balance.
Renin is the aspartyl protease that cleaves angiotensinogen
to produce angiotensin I, which is further converted by
angiotensin converting enzyme (ACE) to the potent vaso-
constrictor, angiotensin II. Since angiotensinogen is the
only substrate known for renin and cleavage of angioten-
sinogen by renin is the rate determining step in the RAS,
it is believed that inhibition of renin would be a reasonable
strategy for the control of blood pressure.
Attempts to inhibit renin at ﬁrst concentrated on high
molecular weight transition state mimetics designed from
the angiotensinogen backbone. As is often the case with
peptidomimetics, these inhibitors suﬀered from poor
pharmacokinetics such as low oral bioavailability and
short duration of action. For a long time, these observa-
tions led many to believe that renin was an undruggable
target. Recently, in 2006, Novartis Pharmaceuticals ﬁled
the ﬁrst NDA for a renin inhibitor to treat hypertension.
Tekturna (Aliskerin) was approved in March 2007 and
represents the ﬁrst of a new structural class of antihyper-doi:10.1016/j.comche.2007.08.001
E-mail: nterrett@ensemblediscovery.comtensive drugs. Based on the positive results exhibited by
Tekturna, interest has been rekindled in renin as a viable
drug target for the control of hypertension.
Recent work1 describes eﬀorts into the discovery of novel
small molecule renin inhibitors for the treatment of hyper-
tension. In this paper, an HTS campaign was undertaken
and (i) was identiﬁed as a weak hit (IC50 = 27lM), repre-
senting a novel small molecule starting point. Parallel
chemistry was then undertaken to optimise this hit. A series
of reductive aminations was used to prepare 450 com-
pounds, leading to the identiﬁcation of (ii) which possessed
an IC50 of 4 lM. Utilising X-ray crystallography, molecu-
lar modelling and structures from an earlier series, these
workers were able to identify a new chemotype (iii) which
possessed an IC50 of 650 nM against renin. This compoundN O N O
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side chains were introduced with the intention of probing
for interactions within other areas in the renin catalytic
site. This work subsequently led to the identiﬁcation of
(iv) as one of the most potent inhibitors of renin obtained
in this series, with an IC50 of 91 nM.
1.2. Prodrug-based design, synthesis and biological evalua-
tion of novel factor Xa inhibitors
Thromboembolic diseases, such as ischemic stroke and
deep vein thrombosis result from intravascular clot forma-
tion. Such clot formation is a major cause of morbidity and
mortality in patients in the industrialised world. Until
recently, the main medical strategy for treating and pre-
venting such disease has been the use of the anticoagulants
heparin, low molecular weight heparins, and the vitamin K
antagonist warfarin.
All of these drugs however, have therapeutic limitations.
Heparin administration for example, does not allow for
an oral route of administration. The use of warfarin as a
treatment suﬀers from a slow onset of action and also
requires individual dose titration and periodic monitoring
due to its indirect mechanism of action. Thus, the search
for novel, orally active anticoagulants that directly inhibit
blood coagulation enzymes has emerged as a very active
area of current research in drug discovery.
Thrombin, which promotes blood clot formation by cata-
lysing the conversion of ﬁbrinogen to insoluble ﬁbrin as
well as strongly inducing platelet aggregation, plays a cen-
tral role in thrombosis. However, direct thrombin inhibi-
tors display a tendency to prolong bleeding at levels
approaching the eﬀective dose. An attractive alternative
to direct thrombin inhibition is blocking the biosynthesis
of thrombin itself. Thrombin formation from prothrombin
in the prothrombinase complex is catalyzed by factor Xa
(fXa). Since fXa inhibitors aﬀect coagulation speciﬁcally
and do not aﬀect platelet function, they theoretically have
less potential to increase the risk of bleeding. Thus, fXa
has emerged as an attractive target for the treatment of
arterial and venous thrombosis.
Recent work2 has utilised compound (v) as a starting point
for drug design optimisation. These researchers planned
that the benzamidine group of (v) would be transformed
into an N-hydroxybenzamidine, to enable a prodrug strat-
egy. To date there have been no pro-moieties revealed for
the acetimidoyl group contained within (v), so surrogates
for the N-acetimidoylpiperidine moiety were sought. A fur-
ther round of design exploited the knowledge that com-
pounds with amidine groups can cause cardiovascular
side eﬀects such as reduced blood pressure and heart rate,
probably because of the high basicity of the amidine group.
The introduction of an acidic carboxyl group into the ami-
dine derivative with a consequential reduction of the basi-
city of the whole compound is an important step for the
avoidance of these side eﬀects.
In order to optimise compounds based on this design
hypothesis, a library of piperidine derivatives typiﬁed bytemplate (vi) were prepared using solid-phase parallel syn-
thesis. All compounds synthesised were tested for their po-
tency in inhibiting human fXa in a puriﬁed enzyme system.
The anticoagulant activity for selected compounds was
evaluated by measuring the prolongation of prothrombin
time (PT) in mouse and human plasma. After testing com-
pounds synthesised in these assays, one of the most potent
analogues obtained was (vii)—an N-hydroxyamidine
prodrug.Compound (vii) had no in vitro activity but demonstrated
an evident PT-prolongation eﬀect in mice when adminis-
tered orally. Its parent amidine (viii) showed no oral anti-
coagulant potency. These results indicated that the
prodrug (vii) was absorbed via oral dosing and bioconvert-
ed into the corresponding active compound.2. A summary of the papers in this month’s issue
2.1. Solid-phase synthesis
Treatment of N-arylsulphonylaziridines bearing a,b-unsat-
urated esters with alcohols, thiols or weak acids such as
AcOH in the presence of a catalytic amount of Lewis acids
aﬀords regio- and stereoselectively ring-opened products,
such as d-aminated c-alkoxy-(alkylthio or acetoxy)-a,b-
enoates. In addition, the regio- and stereoselective ring-
opening reactions can be performed on solid supports
and applied to stereoselective synthesis of (E)-alkene dipep-
tide isosteres.3
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A new eﬀective approach to the synthesis of a small library
of 2-amino-5-arylidene-1,3-thiazol-4(5H)-ones has been
reported using solvent-free reaction conditions under
microwave irradiation. In the ﬁrst step, rhodanines were
subjected to Knoevenagel condensation with aryl aldimines
according to a facile one-pot protocol. Then the (5Z)-
5-arylidene rhodanine derivatives were transformed
directly into the corresponding 2-amino-1,3-thiazol-
4(5H)-ones by sulphur/nitrogen displacement reaction
under microwaves with retention of conﬁguration and
good overall yields.4
The parallel asymmetric synthesis of an array of 30 b-ami-
no acids of high enantiomeric purity using the conjugate
addition of homochiral lithium N-benzyl-N-(a-methylbenz-
yl)amide in the key step has been accomplished. The
experimental simplicity and highly practical nature of the
protocol is demonstrated by the eﬃcient parallel conver-
sion of 15 a,b-unsaturated esters to both enantiomeric
series of the corresponding b-amino acids in high overall
yields and selectivities with minimal puriﬁcation involved
in each step of the reaction protocol.5
A general, mild and eﬃcient protocol for the synthesis of
b-amido ketone libraries has been achieved utilising
tetrachlorosilane and zinc chloride in dichloromethane at
ambient temperature via a one-pot, three-component
condensation of various aldehydes, ketones and nitriles.62.3. Scaﬀolds for combinatorial libraries
The preparation of new Nb-Fmoc-protected aza-b3-amino
acids with proteinogenic side chains as well as their Nb-
Fmoc, Nb-Cbz or Nb-Boc aza-b3-amino esters (from Pro,
Asn, Asp, Glu, Gln) by successive nucleophilic substitu-
tions have been described.7
Chiral 1-phenyl-2-propynylamines are important building
blocks for the synthesis of antifungal and antiaromatase
agents related to bifonazole. A microwave-assisted Cu(I)-
catalysed ‘click chemistry’ approach has been employed
to generate a small library of enantiomerically pure a-[4-
(1-substituted)-1,2,3-triazol-4-yl]benzylacetamides starting
from racemic propargylamines. These compounds could
represent easily accessible intermediates for the synthesis
of new antimicrobial agents.82.4. Solid-phase supported reagents
Polystyrene-IIDQ, a polymer-supported coupling reagent,
has been synthesised in three steps from Merriﬁeld resin
in 86% overall conversion. This reagent eﬃciently coupled
carboxylic acids to amines in good yields and high purities,
required no pre-activation step, and was tolerant of the
order of reagent addition.9
2.5. Novel resins, linkers and techniques
No papers this month.2.6. Library applications
A series of N-alkylbenzenesulphonamides have been devel-
oped from a high throughput screening hit. Classic and
parallel synthesis strategies were employed to produce
compounds with good in vitro and in vivo c-secretase
activity.10
The ﬁrst example of the synthesis of a peptide incorporat-
ing 5-aminolaevulinic acid (5-ALA) using standard Fmoc
solid-phase chemistry has been reported. The synthesised
peptide contains residues 52–58 of the cell-permeable pep-
tide Penetratin and represents a prototype for the enhanced
topical delivery of 5-ALA using such oligopeptide
vectors.11
The design and synthesis of a-helix peptidomimetics using
inverse electron demand Diels–Alder reactions has been
described. The potency of the resulting pyridazine-based
library to disrupt the Bak/Bcl-XL interaction was tested
using an in vitro ﬂuorescence polarization assay.12
A 6,7-diaryl-2,3,8,8a-tetrahydroindolizin-5(1H)-one library
was constructed and tested against the colon cancer cell
line HCT-116 as an initial screen for cytotoxic properties.
Of this library, the parent compound, in which the south-
ern aromatic ring remains unsubstituted, and the northern
aromatic ring carries a 4-methoxy group, exhibited the
most potent cytotoxicity with an IC50 value of 0.39 lM
and this compound displayed promising activity in vivo
in the NCI’s mouse hollow ﬁbre assay.13
Two hundred and ten tertiary amides were prepared on so-
lid phase. When tested on human recombinant melanocor-
tin receptors all the tertiary amides showed some binding
aﬃnities; for the highest aﬃnity compounds the Kis
reached 400 nM on MC1, 2 lM on MC3 and 1 lM on
MC4 and MC5 receptors. cAMP assays of some of the title
compounds showed that the tertiary amides are melano-
cortin receptor antagonists on the four MC receptor
subtypes.14
A library of cyclic CCK8 analogues, containing unnatural
amino acids in the peptide sequence, has been prepared
using solid-phase synthesis. The structure of these cyclic
peptides is based on a previously synthesised compound,
cyclo-CCK8, selective for CCK1 receptor. Structure–activ-
ity investigations have been performed by evaluating the
binding properties of the new analogues.15
Variants of trans-acting hammerhead ribozymes were
modiﬁed with Locked Nucleic Acid (LNA) nucleotides to
reduce their size, to improve access to their RNA target
and to explore combinational properties of binary
constructs. Eﬃcient, binary hammerhead ribozymes were
pursued in a combinatorial approach using a 6-times 5
library, which was analysed by considering the best combi-
nations, buﬀer conditions and fragment ratios.16
The medical uses of betulinic acid and its derivatives are
limited because of their poor solubility and pharmaco-
kinetic properties. In order to overcome these deﬁciencies,
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betulin, betulinic acid, allobetulin and 28-oxoallobetulin
based on six diﬀerent natural sugar residues, were synthes-
ised and studied for in vitro anticancer activity.17
Starting from an established series of non-steroidal gluco-
corticoid receptor (GR) agonists, a large array has been
designed where a metabolically labile benzoxazinone
moiety was replaced. Initial hits bound to GR but lacked
agonist activity. Following two further iterations, potent
GR agonists were discovered with NFjB agonism.18
MEN 15596 is a small molecule, potent and selective antag-
onist of NK2 receptor, possessing high aﬃnity and potency
at the guinea-pig and human receptors whose pharmaco-
logical characterisation has been recently published. A
corresponding class of compounds has been derived from
a tri-peptide library and the ﬁrst optimisation round under-
taken to improve both in vitro activity and physicochemi-
cal properties.19
Pyrrolotriazine dual EGFR/HER2 kinase inhibitors with a
5-((4-aminopiperidin-1-yl)methyl) solubilising group have
been found to be superior to analogues with previously
reported C-5 solubilising groups. New synthetic methodol-
ogy has been developed for the parallel synthesis of C-4
analogues with the new solubilising group. Interesting
new leads were evaluated in tumour xenograft models
and a C-4 aminoﬂuorobenzylindazole was found to exhibit
the best antitumour activity.20References
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